Oruka Therapeutics, Inc. (NASDAQ:ORKA) Receives Average Rating of “Moderate Buy” from Analysts

Shares of Oruka Therapeutics, Inc. (NASDAQ:ORKA) have received an average rating of “Moderate Buy” from the eleven ratings firms that are covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation and ten have assigned a buy recommendation to the company. The average 1 year price target among analysts that have covered the stock in the last year is $134.30.

Several research analysts have recently commented on the company. UBS Group lifted their target price on Oruka Therapeutics from $100.00 to $130.00 and gave the stock a “buy” rating in a research note on Wednesday, July 1st. Weiss Ratings raised Oruka Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, July 15th. Wall Street Zen downgraded shares of Oruka Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, June 13th. Guggenheim set a $200.00 target price on shares of Oruka Therapeutics and gave the stock a “buy” rating in a research note on Monday, April 27th. Finally, Wedbush set a $165.00 target price on shares of Oruka Therapeutics in a report on Monday, April 27th.

Insider Activity at Oruka Therapeutics

In other Oruka Therapeutics news, insider Joana Goncalves sold 7,947 shares of the company’s stock in a transaction on Monday, June 15th. The stock was sold at an average price of $69.28, for a total value of $550,568.16. Following the transaction, the insider directly owned 32,718 shares of the company’s stock, valued at $2,266,703.04. This represents a 19.54% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Lawrence Otto Klein sold 1,729 shares of the stock in a transaction on Monday, June 15th. The stock was sold at an average price of $69.69, for a total value of $120,494.01. Following the transaction, the chief executive officer owned 925,580 shares in the company, valued at $64,503,670.20. The trade was a 0.19% decrease in their position. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last three months, insiders have sold 188,406 shares of company stock valued at $12,019,683. 23.49% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Oruka Therapeutics

A number of hedge funds have recently bought and sold shares of the business. Viking Global Investors LP bought a new position in Oruka Therapeutics in the 3rd quarter valued at about $51,280,000. Paradigm Biocapital Advisors LP bought a new stake in shares of Oruka Therapeutics during the 4th quarter worth approximately $51,840,000. Remedium Capital Partners LLC bought a new stake in shares of Oruka Therapeutics during the 4th quarter worth approximately $47,054,000. Deep Track Capital LP boosted its position in shares of Oruka Therapeutics by 38.4% during the 3rd quarter. Deep Track Capital LP now owns 2,654,781 shares of the company’s stock worth $51,051,000 after acquiring an additional 735,983 shares in the last quarter. Finally, State Street Corp boosted its position in shares of Oruka Therapeutics by 112.2% during the 4th quarter. State Street Corp now owns 1,383,847 shares of the company’s stock worth $41,944,000 after acquiring an additional 731,819 shares in the last quarter. 56.44% of the stock is owned by institutional investors.

Oruka Therapeutics Stock Performance

Shares of NASDAQ:ORKA opened at $92.16 on Friday. Oruka Therapeutics has a 52-week low of $12.84 and a 52-week high of $97.78. The company has a market capitalization of $5.56 billion, a P/E ratio of -47.50 and a beta of -0.35. The company has a 50-day simple moving average of $75.38 and a 200 day simple moving average of $55.48.

Oruka Therapeutics (NASDAQ:ORKA) last announced its quarterly earnings results on Wednesday, May 13th. The company reported ($0.48) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.52) by $0.04. As a group, equities analysts forecast that Oruka Therapeutics will post -2.06 earnings per share for the current year.

Oruka Therapeutics Company Profile

Oruka Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of novel peptide‐based therapies for oncology. The company’s proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell‐permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”

The company’s lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.